|
Education and training |
|
Undergraduate |
1974 - 1980 |
Ptychion Iatrikis (Medical Diploma), University of Athens ( School of Medicine ) ysl outlet |
|
Postgraduate |
1982 - 1983
|
Senior House Officer (Basic Surgery Specialty Training, University Hospital of Ioannina) |
1983 - 1989 |
Postgraduate specialist training in surgery ( Johann-Wolfgang-Goethe University Hospital , Frankfurt am Main , Germany ) |
1984 - 1988 |
German Doctorate title (Dr.med) ? PhD, Johann-Wolfgang-Goethe University , Frankfurt am Main , Germany ) |
1996 - 1997 |
Postgraduate Research & Training, ( T.U. Munchen University Hospital , M.H. Hannover University Hospital , J.W. Goethe University Hospital ) |
|
Work experience |
1990 - Today |
Lecturer, Assistant Professor, Associate Professor of Surgery in Department of Surgery, University of Ioannina , Greece . |
|
|
| |
Scientific Research Activity |
| 1984 - 1999 |
Clinical Research and Practice based on traditional biology, genetics and medicine |
2000 - 2006 |
Reductionist genetics and molecular biology based on single genes or single components of a system of interest. |
| 2007 - 2012 |
Shifting from reductionist to systems science, genome architecture and personalized medicine.
Protein-protein interactions and signal transduction interactions network (interactome), gene-gene interactions, molecular networks, dynamics of genome-lifestyle network. |
| 2012 |
Scientific Director and co-founder of the ?Center of Biosystems & Synthetic Genomic Network Medicine? at Ioannina University. |
| |
|
Stepwise progress from Traditional Research to Precision Oncology |
|
Scientific Research area |
Papers |
Citations |
1985 – 2006 |
CONVENTIONAL CLINICAL & SURGICAL ONCOLOGY RESEARCH: Clinical practice |
72 |
4387 |
2001 – Today |
Personalized Cancer Medicine: Combination of clinico-pathologic and single – gene mutated/amplified genes. Prophylactic and therapeutic surgery for hereditary cancer syndromes, targeted drugs |
68 |
2540 |
2007 – Today |
Molecular interaction networks |
8 |
65 |
2008 – 2011 |
Genome-Wide Association Studies (GWAS) |
17 |
208 |
2010 – Today |
Precision Cancer Medicine: Static and Spatiotemporal genome analysis with conventional and breakthrough NGS systems. Intratumor heterogeneity (MR-NGS, single-cell DNA/RNA seq), serial cfDNA-NGS, comprehensive intra-patient heterogeneity, coding and non-coding genomic and transcriptional heterogeneity. Integration of Hi-C and CRISPR-Cas9 for understanding regulatory networks and future development of non-linear transcriptional network-based next-generation drugs. |
85 |
2100 |
Total |
|
250 |
9300 |
|
|
| |
|
|
BREAKTHROUGH proposed concepts - models |
1998 |
New concept of D2 gastrectomy effectiveness on gastric cancer.
Roukos DH, Lorenz M, Encke A. Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery. 1998 May;123(5):573-8. |
2010 |
Novel clinico-genome model of non-linear genotype - phenotype map on exact prediction of individualized drug resistance and relapse.
Roukos DH. Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn. 2010 Jan;10(1):33-48. doi: 10.1586/erm.09.69. Review. |
|
New intra-patient genomic heterogeneity concept: Translational implications.
|
2017 |
a. Roukos DH. Spatiotemporal Diversification of Intrapatient Genomic Clones and Early Drug Development Concepts Realize the Roadmap of Precision Cancer Medicine. Drug Discov Today. 2017 Aug; 22(8): 1148-1164. doi: 10.1016/ j.drudis.2017.03.014. |
2021 |
b. Kyrochristos ID, Glantzounis GK, Goussia A, Eliades A , Achilleos A, Tsangaras K , Hadjidemetriou I, Elpidorou M, Ioannides M, Koumbaris G,Mitsis M, Patsalis P. C. ,Roukos DH. Proof-of-concept pilot study on comprehensive spatiotemporal intra-patient heterogeneity for colorectal cancer with liver metastasis. MedRxiv.org.
|
| |
|
|
Evaluator
i) Evaluator of research projects with both remote evaluation and active participation in consensus meetings
1. Evaluator in EU research projects (Health-FP7-INNOVATION-1-2-Systems Medicine and Personalized Medicine (2011, 2012, Experts panel consensus meetings, Brussels ) and Horizon 2020
2. Evaluator in France "Agence Nationale de la Recherche" (ANR) research projects (Equipex 2011 ANR 2 Experts panel consensus meetings, Paris 20-21 Sept., and 30 Nov.-2 Dec. 2011), and 4 projects of " Institut National de la Sant? et de la Recherche M?dicale" (INSERM) of 'Physique-Cancer' Program.
3. Evaluator in Italy [Ministry for Education University and Research (MIUR)].
ii) Remote evaluation - Reviewer of national research projects
Reviewer (with honorarium): Research projects from European countries (UK, Italy, The Netherlands) and Asian countries (Singapore, Taiwan, Hong-Kong).
|
| |
|
|
Journals Reviewer
Reviewer in high-impact journals (Nature Biotechnology, Nature Reviews Genetics, Lancet Oncology [honorarium for fast-track articles], Nature Reviews Clinical Oncology, Nature Communications, Nature Protocols) and multiple other journals. |
| |
Editorial Board Member |
| |
Organazing Committee Member |
| |
Invited Speaker in international meetings |
| |
International recognition. Leading Expert |
Assessment criteria |
Database |
| |
PubMed (MEDLINE) |
ISI web of Knowledge |
Scopus |
| Publications |
255 |
265 |
295 |
| Citations |
NA |
9017 |
9886 |
| Hirsch (h-factor) |
NA |
71 |
78 |
